Ubiquitin fusion-based vaccine system
AssigneeProteinix, Inc.
InventorsJohn H. Kenten, Alfonso Tramontano, Aprile L. Pilon, Gerald L. Lohnas, Steven F. Roberts
Life of this patent
Estimating the term…
Abstract
Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.
Claims16
A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical epitopes;
- and
- b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical or non-identical epitopes;
- and
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical or non-identical epitopes, the epitope-containing segments being fused to ubiquitin at fusion sites selected from the group consisting of the N-terminus and an internal fusion site;
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising one or more identical or non-identical epitopes, the epitope-containing segment being fused to ubiquitin at N-terminus of ubiquitin;
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin having the peptide QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPGC fused via its N terminus to the C-terminal residue of ubiquitin;
- and
- (b) administering the conjugate of step (a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for reducing levels of a predetermined protein in an animal relative to base-line levels, comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical epitopes;
- and
- b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for reducing levels of a predetermined protein in an animal relative to base-line levels, comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical or non-identical epitopes;
- and
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for reducing levels of a predetermined protein in an animal relative to base-line levels, comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical or non-identical epitopes, the epitope-containing segments being fused to ubiquitin at fusion sites selected from the group consisting of the N-terminus and an internal fusion site;
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
A method for reducing levels of a predetermined protein in an animal relative to base-line levels, comprising:
- (a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising one or more identical or non-identical epitopes, the epitope-containing segment being fused to ubiquitin at N-terminus of ubiquitin;
- (b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
Dependencies are inferred from the claim text.